Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor

Joel G.R. Weaver, … , Guido Kroemer, Andrew D. Badley


Inhibitors of HIV protease have been shown to have antiapoptotic effects in vitro, yet whether these effects are seen in vivo remains controversial. In this study, we have evaluated the impact of the HIV protease inhibitor (PI) nelfinavir, boosted with ritonavir, in models of nonviral disease associated with excessive apoptosis. In mice with Fas-induced fatal hepatitis, Staphylococcal enterotoxin B–induced shock, and middle cerebral artery occlusion–induced stroke, we demonstrate that PIs significantly reduce apoptosis and improve histology, function, and/or behavioral recovery in each of these models. Further, we demonstrate that both in vitro and in vivo, PIs block apoptosis through the preservation of mitochondrial integrity and that in vitro PIs act to prevent pore function of the adenine nucleotide translocator (ANT) subunit of the mitochondrial permeability transition pore complex.

Find the latest version:

http://jci.me/22954/pdf
Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor

Joel G.R. Weaver,1,2,3 Agathe Tarze,4 Tia C. Moffat,5 Morgane LeBras,4 Aurelien Deniaud,4 Catherine Brenner,4 Gary D. Bren,2 Mario Y. Morin,5 Barbara N. Phenix,4 Li Dong,3,6 Susan X. Jiang,7 Valerie L. Sim,8 Bogdan Zurakowski,7 Jessica Lallier,8 Heather Hardin,9 Peter Wettstein,9 Rolf P.G. van Heeswijk,9 Andre Douen,3 Romano T. Kroemer,10 Sheng T. Hou,7 Steffany A.L. Bennett,5 David H. Lynch,11 Guido Kroemer,12 and Andrew D. Badley2,13

1Division of General Surgery, University of Ottawa, Ottawa, Ontario, Canada. 2Division of Infectious Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, USA. 3Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada. 4Université de Versailles Saint-Quentin-en-Yvelines, Versailles, France. 5Neural Regeneration Laboratory, Department of Biochemistry, Microbiology, and Immunology, and 6Department of Pathology, University of Ottawa, Ottawa, Ontario, Canada. 7Experimental Stroke Group, National Research Council Institute for Biological Sciences (NRC/IBS), National Research Council of Canada, Ottawa, Ontario, Canada. 8Division of Neurology, Ottawa Hospital, Ottawa, Ontario, Canada. 9Amnis Corp., Seattle, Washington, USA. 10Institut Gustave Roussy, Villejuif, France. 11Translational Program in Immunology and Biodefense, Mayo Clinic and Foundation, Rochester, Minnesota, USA.

Inhibitors of HIV protease have been shown to have antiapoptotic effects in vitro, yet whether these effects are seen in vivo remains controversial. In this study, we have evaluated the impact of the HIV protease inhibitor (PI) nelfinavir, boosted with ritonavir, in models of nonviral disease associated with excessive apoptosis. In mice with Fas-induced fatal hepatitis, Staphylococcal enterotoxin B–induced shock, and middle cerebral artery occlusion–induced stroke, we demonstrate that PIs significantly reduce apoptosis and improve histology, function, and/or behavioral recovery in each of these models. Further, we demonstrate that both in vitro and in vivo, PIs block apoptosis through the preservation of mitochondrial integrity and that in vitro PIs act to prevent pore function of the adenine nucleotide translocator (ANT) subunit of the mitochondrial permeability transition pore complex.

Introduction
The abnormal regulation of apoptosis is thought to contribute to a variety of pathologic disease processes in vivo. HIV-induced CD4 T cell depletion and consequent immunodeficiency is one such disease state in which excessive apoptosis has been implicated. Current therapies for HIV not only reduce HIV replication but may also directly impact apoptosis; indeed, many groups have now reported that HIV protease inhibitors (PIs) can inhibit apoptosis at concentrations similar to those that are commonly seen in the plasma of patients receiving such treatments (reviewed in ref. 1). Paradoxically, such agents may also induce apoptosis, particularly of transformed cells, when used at higher doses (2–5).

Studies by several groups have investigated the potential mechanisms by which PIs may inhibit apoptosis, yielding different results. Proposed mechanisms include altered transcriptional regulation of key apoptosis regulatory proteins (5–7) and/or direct inhibition of the apoptosis enzyme ICE (8, 9) and/or calpain (10). Such theories cannot fully account for the ability of PIs to inhibit diverse apoptotic stimuli (reviewed in ref. 1) or the lack of enzymatic inhibition of recombinant caspases in vitro (11). According to another proposed mechanism to account for apoptosis inhibition, PIs alter the propensity of mitochondria to transduce apoptotic signals. This latter model is supported by the findings that PIs are able to block Fas-induced apoptosis involving mitochondrial signaling but not Fas-induced apoptosis that is mitochondria independent (11) and that PIs are able to rescue cells from apoptosis induced by mitochondriotoxic agents (5, 12).

Despite these in vitro findings, it remains controversial whether PI therapy for HIV-infected patients offers additional benefits in terms of CD4 T cell reconstitution compared with non-PI–containing regimens of equal antiviral potency (13, 14). Most studies that demonstrate enhanced CD4 T cell improvements in patients receiving PI therapy were retrospective, post-hoc analyses (15), which raises concerns about the methodologies used. Consequently, at least one study was designed to compare CD4 T cell number, activation profile, memory and naive T cell subsets, and apoptosis between patients receiving PI-continuing or PI-sparing regimens (16). No differences were observed between groups regarding CD4 T cell number, activation, or memory or naive subsets; however, within the first week of therapy, significantly less apoptosis was seen in CD4 T cells of patients receiving PI therapy than in patients who did not receive PI therapy (16). Such data are consistent with the postulated antiapoptotic effects of PIs.

The objectives of this study were, first, to evaluate whether PIs were antiapoptotic in vivo by evaluating apoptotic changes in animal models of disease that are associated with excessive apopto-

Nonstandard abbreviations used: ΔΨm, membrane permeability; ANT, adenine nucleotide translocator; AST, aspartate amino transferase; ATR, atracyloside; D-gal, D-galactosamine; MCAO, middle cerebral artery occlusion; NPI, nelfinavir; PBR, benzodiazepine receptor; PI, protease inhibitor; PTPC, permeability transition pore complex; RIT, ritonavir; RT, room temperature; SEB, Staphylococcal enterotoxin B; STS, staurosporine; TTC, 2,3,5-triphenyltetrazolium; VDAC, voltage-dependent anion channel.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 115:1828–1838 (2005).

doi:10.1172/JCI22954.
sis but that do not depend upon viral replication and, second, to evaluate the mechanisms involved.

**Results**

As mouse metabolism of PIs differs from that of humans, we first performed pharmacokinetic studies of mice treated with nelfinavir (NFV) at doses used in human therapy. Within 1 hour of dosing, mice had undetectable levels of NFV. Therefore, we co-dosed mice with ritonavir (RIT), another PI known to increase PI levels in humans (17). Ultimately, a dose of 125 mg/kg NFV and 13 mg/kg RIT resulted in drug levels similar to those of humans treated with NFV alone (see Methods). This dose was used for in vivo testing.

First, we evaluated the impact of NFV/RIT treatment on CD95/Fas-induced hepatic failure (18–20). Mice received NFV/RIT or vehicle control pretreatment for 24 hours followed by treatment with 6 or 12 µg of IV Jo-2 anti-Fas antibody. Control animals died in a dose-dependent manner, whereas NFV/RIT-pretreated animals displayed superior survival compared with controls (Figure 1A). Moreover, survival of mice treated with RIT (13 mg/kg) was similar to that of controls, which indicates that NFV was responsible for the observed improved survival. Importantly, all mice that died did so within 72 hours, which indicates that NFV/RIT truly prevents rather than delays Jo-2–induced hepatotoxicity and death. In parallel, groups of 10 mice received 2.5, 5, or 7.5 µg of IV Jo-2 with or without NFV/RIT pretreatment. Mice were sacrificed at 4 or 24 hours and analyzed for serum biochemistry, H&E histology, and apoptosis by TUNEL staining. Serum glucose, blood urea nitrogen, creatinine, phosphorus, total protein, albumin, globulin, bilirubin, and cholesterol levels were similar in the 2 groups (data not shown).

However, NFV/RIT-pretreated mice had attenuated elevations in serum aspartate amino transferase (AST) at both 4 and 24 hours compared with control mice (P < 0.03; Figure 1B), reduced evidence of hepatitis at 48 hours on H&E histology, and a reduced quantity of TUNEL-positive hepatocytes from a mean of 50% to 15% (measured in 5 mice per group; P = 0.002; data not shown).

To assess whether NFV/RIT protection extended to other apoptotic disease processes, we treated mice with the bacterial superantigen *Staphylococcal enterotoxin B* (SEB) in the presence or absence of NFV/RIT. Systemic treatment with SEB results in shock and the selective apoptosis of V-β8–positive T cells (21). When coadministered with d-galactosamine (D-gal), SEB injection also results in death (22, 23). Following administration of SEB, apoptosis was measured by TUNEL assay in the V-β8 and V-β3 subsets of splenocytes. Four hours following SEB treatment, 72.6% of V-β8 cells were TUNEL positive, whereas 21.7% of V-β3 cells were TUNEL positive (n = 3; P < 0.05), which indicates that SEB selectively induced death in V-β8 cells. Parallel groups of mice were pretreated for 24 hours with NFV/RIT, vehicle control, NFV alone, or RIT alone, followed by treatment with 20 mg D-gal and 6.5 µg SEB. NFV/RIT-treated mice had improved survival compared with vehicle control (89%, n = 9 vs. 27%, n = 11; P < 0.01). Survival of vehicle-treated mice was not significantly different from that of mice treated with NFV alone (30%; n = 10; P = 0.25) or RIT alone (20%; n = 10; P = 0.25). In addition, NFV/RIT, when given 4 hours after SEB/D-gal, was associated with improved survival compared with control (60%; n = 10; P < 0.05; Figure 1C). NFV/RIT treatment was also associated with reduced V-β8 T cell apoptosis compared with vehicle control (Figure 1D).
Given the substantial reduction in apoptosis and the improvement in survival afforded by NFV/RIT in the Jo-2 and SEB models, we next assessed the impact of NFV/RIT on cerebral injury in the middle cerebral artery occlusion (MCAO) model of focal ischemia. C57BL/6 mice were pretreated by oral gavage with either NFV/RIT or vehicle (2% EtOH) 24, 16, and 8 hours before sham or MCAO surgery (vehicle control, sham surgery, \( n = 7 \); vehicle control, MCAO surgery, \( n = 10 \); NFV/RIT, sham surgery, \( n = 7 \); NFV/RIT, MCAO surgery, \( n = 10 \)). A fifth cohort received MCAO surgery without NFV/RIT or vehicle pretreatment (\( n = 5 \)). Infarct size in the striatum and cortex was assessed by 2,3,5-triphenyltetrazolium (TTC) staining (Figure 2A). After 1 hour of MCAO followed by 24 hours of reperfusion, vehicle-treated animals or mice that were not orally gavaged exhibited a 34% reduction in TTC staining relative to the control (Figure 2A). Infarct size as measured by TTC staining was 23% (\( P < 0.05 \)) compared with control in the NFV/RIT treatment group (Figure 2B). We next assessed neuronal number in the striatum by immunodetection of the neuron-specific marker NeuN (24). Both vehicle- and NFV/RIT-treated animals exhibited a comparable, approximately 20% loss of NeuN-positive neurons after 1 hour of MCAO and 24 hours of reperfusion (Figure 2, C and D). However, NFV/RIT significantly reduced apoptotic-like death, as detected by TUNEL/NeuN double labeling (Figure 2, C and E). In vehicle-treated animals, 67% of the remaining NeuN-positive neurons in the striatum were actively undergoing DNA fragmentation 24 hours after surgery (Figure 2E); however, only 24% (\( P < 0.01 \)) of NeuN-positive neurons were TUNEL reactive in NFV/RIT-treated mice (Figure 2E). Finally, we determined whether the neuroprotection afforded by NFV/RIT pretreatment manifested in improved behavioral recovery. Neurological deficits in motor function were assessed using an expanded 6-point scale modified from refs. 25, 26 (see Methods). Animals were tested immediately after 0.5 hours of MCAO followed by 24 hours of reperfusion, NFV/RIT exhibit significant behavioral improvement relative to 0.5 hours or vehicle-treated cells (\( P < 0.05 \); \( * P < 0.01 \)), ANOVA, post-hoc Tukey test. Data represent mean ± SEM.
vitro with CH-11 anti-Fas antibody with the apoptotic signaling in hepatocytes isolated from mice treated in vivo with IV Jo-2 anti-Fas antibody. In vitro pretreatment of Jurkat T cells with NFV followed by stimulation with CH-11 resulted in a dose-dependent reduction in apoptosis (Figure 3A). NFV-pretreated Jurkat T cells had similar caspase-8 cleavage and activity and Bid cleavage as seen in vehicle control cells. However, mitochondrial membrane permeability ($\Delta$Ψm), cytochrome c release, caspase-9 cleavage, and caspase-3 cleavage and activity were all reduced by NFV pretreatment (Figure 3, B–E), which suggests that NFV inhibition of apoptosis occurs upstream of caspase-9 in the apoptotic pathway. Moreover, transient expression of caspase-9 in Jurkat T cells resulted in hypoploidy that was not inhibited by NFV yet was inhibited by the caspase-9 inhibitor, LEHD, which confirms that NFV blocks apoptosis upstream of caspase-9 activation. Similar analyses were performed ex vivo on hepatocytes isolated from mice receiving Jo-2 with NFV/RIT or control (as in Figure 1) were also analyzed for caspase-8 and caspase-3 activity (F) and loss of $\Delta$Ψm retention (G). $^\dagger$P < 0.005.

**Figure 3**

Effect of NFV on apoptotic signaling events in vitro and in vivo. (A) Jurkat T cells were stimulated with agonistic anti-Fas antibody (CH-11) in the presence or absence of varying concentrations of PI and analyzed for annexin positivity. *P < 0.05. (B) Western blot analysis of the Fas signaling events of caspase-8, -9, and -3 cleavage, Bid cleavage, or cytosolic translocation of cytochrome c (cyt c) in Jurkat T cells treated or not treated with CH-11 with or without NFV. tBid, truncated Bid. (C) Caspase-8 and caspase-3 activity was also assessed in Jurkat T cells stimulated with CH-11 in the presence or absence of NFV. *P < 0.01. (D) Jurkat cells were transiently transfected by a GFP plasmid or a caspase-9 GFP plasmid, treated or not treated with 7 µM NFV or 100 µM LEHD, cultured for 6 hours, stained with PI, and analyzed by cytofluorometry for hypoploidy. (E) Jurkat cells stimulated with CH-11 in the presence or absence of NFV were analyzed for loss of $\Delta$Ψm retention. Hepatocytes isolated from mice receiving Jo-2 with NFV/RIT or control were also analyzed for caspase-8 and caspase-3 activity (F) and loss of $\Delta$Ψm retention (G). $^\dagger$P < 0.005.
and determined that NFV inhibits mitochondrial swelling induced by all 3 stimuli (Figure 4A). Inhibition of Bax-induced apoptosis might indicate a loss of Bax activation and translocation or a lack of effect of Bax on ∆Ψm (reviewed in refs. 27, 28). We therefore directly assessed whether NFV inhibited mitochondrial translocation and activation of Bax. We stimulated cells through the Fas receptor in the presence of NFV or DMSO vehicle control and analyzed them for nuclear morphology using Hoechst 33342 staining and for Bax activation by immunofluorescence using an antibody specific for the activated conformation of Bax. Control (untreated) cells had no evidence of Bax activation and had intact nuclei. Fastimulated cells exhibited both Bax activation with punctate Bax staining and fragmented nuclei, consistent with apoptosis. NFVpretreated cells showed punctate staining for activated Bax, yet no nuclear fragmentation was observed (Figure 4B).

Furthermore, we induced apoptosis by overexpression of Bax. Bax was cotransfected with GFP, and consequently apoptosis was assessed specifically in the GFP-positive cell populations. NFV treatment inhibited ∆Ψm loss induced by the overexpression of Bax (Figure 4C). Together, therefore, our data indicate that the antiapoptotic action of NFV occurs at the level of mitochondria, downstream of Bax translocation and activation, but invoking mitochondrial ∆Ψm.

Mitochondrial loss of ∆Ψm is coincident with the opening of the mitochondrial permeability transition pore complex (PTPC). These events allow the release of cytochrome c into the cytosolic compartment, which, in the presence of dATP, results in the formation of a complex between Apaf-1 and procaspase-9 known as the apoptosisosome. This results in activation of procaspase-9 (29, 30), which in turn activates the downstream effector caspase-3 (31). A key regulator in this process, therefore, is the mitochondrial PTPC, which is composed of the peripheral benzodiazepine receptor (PBR), adenine nucleotide translocator (ANT), voltage-dependent anion channel (VDAC), as well as other proteins (32). We therefore assessed apoptosis in the presence or absence of NFV in WT yeast or yeast deficient in both isoforms of VDAC or all 3 isoforms of ANT. HIV Vpr initiates apoptosis through binding ANT with affinities in the nanomolar range (33), whereas Vpr does not bind to VDAC in vitro (33). Consistent with prior reports, Vpr was able to induce yeast death only if ANT was present (Figure 5, A and B). Since VDAC and ANT physically interact, and form the principal pore channel of PTPC in a cooperative manner (34, 35), absence of VDAC also abrogated the ability of Vpr to cause death (Figure 5A). H2O2 also induces apoptosis in an ANT-dependent manner, potentially through oxidation of thiol groups within ANT (36–38). Like Vpr, H2O2 only induced apoptosis if ANT was present, and VDAC was required as well (Figure 5A). Next, we assessed the ability of NFV to inhibit apoptosis in WT yeast following stimulation with Vpr or H2O2. WT yeast underwent Vpr- and H2O2-induced apoptosis, which was inhibited in a dose-dependent manner by NFV treatment (Figure 5B), arguing that NFV requires the presence of ANT, VDAC, or both.

To further examine the involvement of the components of the PTPC in NFV-mediated inhibition of apoptosis, we next used chemical ligands that selectively interact with different components of the PTPC, causing it to open and resulting in subsequent loss of ∆Ψm. PK11195 is an agonist of the PBR (39, 40), ATR is an agonist of ANT (41), and staurosporine (STS) is an agonist of VDAC (42, 43). Jurkat T cells were pretreated with NFV or vehicle control and subsequently treated with these agonists and analyzed for apoptosis. Treatment with PK11195 or STS resulted in apoptosis (Figure 6A), loss of ∆Ψm (Figure 6B), cytochrome c release, caspase-9 cleavage, caspase-3 cleavage and activation, and poly (ADP-ribose) polymerase (PARP) cleavage (Figure 6, C and D) that were not altered by NFV, which suggests that NFV does not alter PBR or VDAC-initiated loss of ∆Ψm. Repeating these experiments with the ANT-specific agonist ATR resulted in a loss of ∆Ψm, cytochrome c release, caspase-9 cleavage, caspase-3 cleavage, PARP cleavage, and caspase-3 activation that were inhibited by NFV (Figure 6, A–D). These differential results suggest that NFV acts as an inhibitor of ANT-dependent PTPC opening.

To confirm that NFV can act specifically with ANT to inhibit its pore function, we used proteoliposomes reconstituted with either entire PTPC or with ANT alone, which release a fluorescent dye following pore opening (44). Consistent with our cellular data, treatment of PTPC liposomes with ATR resulted in significant fluorescence release that was progressively inhibited by a range (0.1–10 µM) of increasing doses of NFV (Figure 7A). We
next assessed whether NFV could act directly upon ANT to inhibit its pore function. ANT liposomes were created and treated with 2 distinct ANT ligands, ATR (Figure 7B) and Vpr (Figure 7C). Each ligand resulted in a dose-dependent release of fluorescence from the ANT liposomes that in turn was inhibited ($P < 0.05$) in a dose-responsive manner by NFV.

**Discussion**

Here we provide evidence that HIV PIs have the ability to meaningfully impact apoptosis in vivo in a variety of animal models and that this effect localizes to mitochondrial release of proapoptotic factors. Moreover, our in vitro data suggest that NFV acts to inhibit the pore function of the ANT subunit of the mitochondrial PTPC. This effect of NFV permits the premitochondrial signaling events of death receptor–initiated apoptosis yet inhibits mitochondrial loss of $\Delta \Psi_{m}$ and the subsequent formation of the apoptosome and activation of caspase-9 and caspase-3.

This mechanism of action offers insight into the question of whether cells that have undergone some changes of apoptosis (e.g., caspase-8 activation) but not others (e.g., $\Delta \Psi_{m}$) will still be fated to death. Hepatocytes from Jo-2–treated mice dosed with NFV/RIT maintained caspase-8 activation but not the mitochondrial and postmitochondrial signaling events. Consequently, analysis of these mice affords an opportunity to address the long-term outcome of tissues rescued from death by NFV/RIT treatment. First, since no mortality was observed between days 3 and 30, NFV/RIT treatment prevents rather than delays death. Second, serum AST remains lower in NFV/RIT-treated mice, which suggests maintenance of hepatocyte viability and function. Third, hepatic histology of NFV/RIT-treated mice is preserved at day 30, which demonstrates a lack of delayed tissue damage in mice surviving as a consequence of NFV/RIT therapy. Comparable results were...
observed in the MCAO model of focal ischemia. NFV/RIT did not affect necrotic loss or neuronal damage in the ischemic core, nor did pretreatment improve behavioral indices when animals were tested after recovery from the anesthetic, 30 minutes after the 1-hour occlusion. However, NFV/RIT significantly reduced subsequent apoptotic-like death observed over the 24-hour reperfusion period, markedly improving neurological scores as a consequence. Therefore, blocking the mitochondrial events of apoptosis represents a viable approach to preventing rather than delaying cell death and a potential means of improving function in pathologic processes involving exaggerated apoptosis.

It is noteworthy that the antiapoptotic effects of NFV/RIT persist even if administered after the apoptosis-initiating event in mice receiving SEB/D-gal, and survival is improved when NFV/RIT is administered 4 hours later. Although the maximum duration between apoptotic insult and NFV/RIT administration that is still associated with improved outcome remains to be defined, these observations suggest the increased likelihood that such agents might afford clinically useful protection.

Recently, the role of ANT in mitochondrial permeability transition has been questioned. Whereas ANT has been widely regarded as being essential for mitochondrial depolarization and consequent cytochrome c release, apoptosis formation, and apoptosis, a recent report directly challenges that role. Mice were constructed with a complete deficiency in both isoforms of ANT within liver tissues (45). Hepatocytes from these mice had compensatory upregulation of cytochrome c and of cytochrome c oxidase. Mitochondria from these livers contain functional PTPCs, which release cytochrome c; however, 3-fold more calcium signal was required to induce the permeability transition than in WT cells. Thus, although the knockout of ANT-1 and ANT-2 genes in hepatocytes does not abolish mitochondrial outer membrane permeabilization induced by calcium in absolute terms, it does significantly reduce the sensitivity of these mitochondria to calcium-induced PTPC opening. Our current data are consistent with some findings discussed in that report; both inhibition of ANT by PIs and genetic absence of ANT result in abrogated mitochondrial response to ANT ligands, including ATR. However, unlike cells from ANT-deficient livers, which remain sensitive to apoptosis induced by Fas ligand and ANT. Computer simulations of the interactions of NFV with ANT indicated a putative binding site on the matrix side of the transporter protein. Based on this simulation, NFV is predicted to bind close to helices 3 and 5 of ANT (Figure 8). Binding also involves part of the loop connecting helices 3 and 4 (loop M2 in Figure 8), which has been proposed as the ADP binding site (37). Several hydrogen bonds appear to be made between NFV and ANT, in particular with residues K162, G242 (backbone), M239 (backbone), and R243 (Figure 8). Hydrophobic contacts between NFV and ANT constitute the segment around S166 as well as the side chain of R139.

Since multiple apoptotic signals, including death receptor ligation, chemotherapeutics, BH3-only Bcl2 family members, UV radiation, and others converge upon mitochondria, drugs that target mitochondrial regulators of apoptosis, such as NFV, are attractive therapeutic candidates. Our data provide the basis for the evaluation of NFV or related compounds as in vivo inhibitors of apoptosis in non-HIV disease states characterized by excessive apoptosis.

Methods

**Mouse treatments**

Mice received either NFV/RIT in 2% ethanol or vehicle control (2% ethanol) by oral gavage every 8 hours. Animal treatments were reviewed and approved by the Mayo Foundation Institutional Animal Care and Use Committee, the NRC/IBS Animal Care Committee, and the University of Ottawa Animal Care Committee. Plasma concentrations of NFV and RIT were measured simultaneously using liquid chromatography with tandem mass spectrometry. The lower limit of quantitation for NFV and RIT was 2.5 ng/ml. The accuracy of quality control samples analyzed simultaneously with the study samples ranged from 83.7% to 107.5% for NFV and 105.0% to 116.5% for RIT. The within-run variability for 3 replicative analyses of the quality control samples was less than 9.7% for both NFV and RIT. This assay has been cross-validated as part of the International Interlaboratory Quality Control Program for Therapeutic Drug Monitoring in HIV Infection (47). To determine a dosing regimen that would result in relevant plasma concentrations, we treated 6- to 8-week-old BALB/c and C57BL/6 mice with 250 mg/kg of NFV (Agouron Pharmaceuticals Inc.) every 8 hours, yet plasma concentrations were undetectable 6 hours after dosing. Since coadministration of RIT in humans significantly increases

**Figure 7**

Effects of NFV on PTPC or ANT pore function. (A) Proteoliposomes containing PTPC complexes were treated with NFV, stimulated with ATR, and analyzed for fluorescence release. Proteoliposomes containing ANT were treated with NFV and analyzed for fluorescence release following stimulation with ATR (B) or Vpr peptide (residues 52–96) (C). Results are representative of 3 independent experiments.
NFV levels compared with NFV alone (48), we treated mice every 8 hours with 125 mg/kg NFV and 13 mg/kg RIT (Abbott Laboratories). Eight-hour NFV trough levels, ranging from 1,199 to 1,258 ng/ml, were comparable to concentrations observed in HIV-infected patients using NFV. We also assessed whether C57BL/6 mice treated with this dose of NFV/RIT achieved detectable drug levels in the brain. NFV and RIT concentrations in brain tissues were determined after the tissues were washed extensively with PBS, blotted dry with filter paper, placed in 5 ml of 0.1 M phosphoric acid, and homogenized using a polytron. Supernatants were analyzed as described above for drug level determination. Analysis of whole brains revealed levels of NFV between 682 and 986 µg/g of brain tissue. We therefore opted to assess the in vivo antiapoptotic effects of the combination of NFV and RIT using this dosing regimen.

Fas-induced liver failure
Six-week-old female C57BL/6 mice (Charles River Laboratories) received the indicated doses of Jo-2 anti-Fas antibody (BD Biosciences — Pharmingen) by tail vein injection. Moribund animals, or animals who survived until the indicated time points, were sacrificed by CO₂ asphyxiation. Clinical chemistries were performed on serum obtained from 3 mice from each treatment group at 4 and 24 hours after Jo-2 injection. Quantitation of hepatocyte apoptosis by TUNEL assay (Roche Diagnostics Corp.) was averaged from results analyses performed in a blinded manner by 4 reviewers.

SEB-induced shock
Six-week-old female BALB/c mice (Harlan) received 20 mg D-gal (Sigma-Aldrich) and 6.5 µg SEB (Toxin Technology Inc.) intraperitoneally. Animals were euthanized if they became moribund, laterally recumbent, or hypothermic (rectal temperature <32°C) at the indicated time points. Spleens were harvested and splenocytes isolated mechanically with plastic mesh. Following red cell lysis and removal of B cells by incubation with nylon wool (1 hour, 37°C; Accurate Chemical and Scientific Corp.), purified T cells were stained with monoclonal anti-mouse V-β8–FITC antibody (clone F23.1), V-β3–FITC antibody (Clone KJ25), or appropriate isotype control (BD Biosciences — Pharmingen) and then washed with PBS and fixed with 1% parafomaldehyde. Dual staining with TUNEL-TMR red (Roche Diagnostics Corp.) was performed as per the manufacturer’s instructions.

Cerebral ischemia produced by MCAO
C57BL/6 mice (20–23 g) were obtained from Charles River Laboratories. Under temporary isoflurane anesthesia, mice were subjected mice to MCAO using an intraluminal filament as previously described (49). After 1 hour of MCAO, the filament was withdrawn, blood flow restored to normal by laser Doppler flowmetry, and wounds sutured. Beginning 24 hours before surgery, mice received 3 oral gavages, 8 hours apart, of either NFV/RIT or vehicle. Following 24 hours of reperfusion, mice were anesthetized with CO₂ and sacrificed by either decapitation or lethal injection with sodium pentobarbital and transcervically perfused with 10 mM PBS (10 mM sodium phosphate and 154 mM NaCl) followed by 3.7% parafomaldehyde in 10 mM PBS. Behavioral impairment following MCAO was assessed at 30 minutes after ischemic surgery when animals had recovered from the anesthetic and 24 hours after reperfusion by 2 investigators blind to the treatment of the mice. A modified 6-point scale was used (25, 26): 0, normal; 1, mild turning behavior with or without inconsistent curling when picked up by tail and less than 50% attempts to curl to the contralateral side; 2, mild, consistent curling and more than 50% attempts to curl to the contralateral side; 3, strong and immediate consistent curling, mouse holds curled position for more than 1–2 seconds, and mouse’s nose almost reaches tail; 4, severe curling progressing into barreling and loss of walking or righting reflex; 5, comatose or moribund. Behavioral scores were averaged within treatment groups for statistical analysis. In unfixed tissue, infarct size was measured by a colorimetric staining method using TTC, as described previously (50). Brains were removed and cut into three 2-mm-thick coronal slices through the striatum, which were separated into left and right hemispheres and stained with 5 ml of 2% TTC per hemisphere for 90 minutes at 37°C. The tissue was rinsed with saline, and the formazan product solubilized in ethanol/DMSO (1:1). After a 24-hour incubation in the dark, the red solvent extracts were diluted 1:20 with fresh ethanol/DMSO solvent in triplicate, absorbance was measured at 485 nm in a spectrophotometer, and the values were averaged. Percent decrease in brain TTC staining was calculated using the following equation: percent decrease = 100 – (absorbance of contralateral hemisphere/absorbance of ischemic hemisphere) × 100; and the values for the ischemic and contralateral sides of the brain in the same animal were compared. Perfused brains were postfixed for 24 hours in 3.7% paraformaldehyde in 10 mM PBS and cryoprotected in 20% sucrose solution in 10 mM PBS containing 0.001% sodium azide. Serial coronal sections (10 µm) were cryostat cut (Leica Microsystems Inc.) and immunolabeled for the neuronal nuclear marker NeuN (Chemicon International) using a Cy3-conjugated anti-mouse IgG secondary antibody (Jackson ImmunoResearch Laboratories Inc.) as described (51). Antibodies were diluted in antibody buffer (10 mM PBS, 0.3% Triton X-100, and 3% BSA). We evaluated immunofluorescence using on a DMRX2 microscope (Leica Microsystems Inc.) equipped for epifluorescence. The number of NeuN-positive/TUNEL-negative cells was counted and tissue area was measured using the Advanced Measurements Module of OpenLab version 3.17 (Improvision) in 2 adjacent sections of both ipsilateral and contralateral striatum and cortex. Means were averaged across treatment groups.

Cell culture and apoptosis induction in vitro
Jurkat T cells (ATCC) were cultured in RPMI media (Mediatech Inc.), supplemented with 10% heat-inactivated FBS (Atlanta Biologicals), and peni-
cillin/streptomycin (Invitrogen Corp.) at 37°C in 5% CO₂. Where indicated, cells were incubated with 7 μM NFV or 20 μM z-VAD-fmk (R&D Systems) or vehicle (DMSO) overnight prior to induction of apoptosis with indicated doses of CH-11 anti-Fas antibody (Upstate), ATR (Sigma-Aldrich), STS (Calbiochem), or PK11195 (Sigma-Aldrich).

**Transfection experiments**

Transient transfection of Jurkat cells with vectors containing a pEGFP gene (pEGFP-N2; BD Biosciences), a Bax-GFP gene (kindly provided by Shige-mi Matsuyama, Research Center for Allergy and Immunology, Kanagawa, Japan; ref. 52), and caspase-9–GFP (kindly provided by P. Mehlen, Apoptosis Cancer and Development Laboratory, Lyon, France; ref. 53). Cells were cultured in RPMI 1640, 10% FBS, and 1% l-glutamine without antibiotics. Two days before transfection, cells were passed at 1.5 × 10⁶ cells/ml. For electroporation, 1 × 10⁹ cells were pelleted, resuspended in 250 μl of 10% FBS-RPMI 1640, mixed with 250 μl of 20 μg DNA, and incubated for 10 minutes at room temperature (RT). The DNA/cell suspension was transferred to a 4-mm cuvette, and electroporation was performed at 10 ms/325 V using a square wave electroporator (Bio-Rad Laboratories). After 10 minutes at RT, cells were diluted to 20 ml in complete medium without antibiotics and cultured at 37°C under 5% CO₂, as previously described (57).

**Mitochondrial swelling**

Mitochondria were purified from BALB/c mouse livers on a Percoll gradient (58) and were stored on ice for up to 4 hours. For determination of large amplitude swelling, 5 μl of mitochondria (0.5 mg protein/ml) was added to 200 μl of swelling buffer [0.2 M saccharose, 10 mM TRIS-3-(N-morpholino)–propanesulfonic acid, 5 mM propidium iodide, 1 mM EGTA, 0.35 mM rotenone, pH 7.4], and light absorption was recorded for 20 minutes at 545 nm in a microtiter plate (TECAN GENios). The loss of absorption induced by 0.5 mM ATR was used as a positive control to define maximal large amplitude swelling. For inhibition experiments, NFV or control was always added before the swelling inducers, Vpr-derived peptide, and ATR.

**Yeast strains and clonogenic assays**

We pre-treated 10⁶ cells/ml of Saccharomyces cerevisiae M22-2-1 (genotype MATa ade2 leu2 lys2 his4 trpl ura3 canr, por1:LEU2, por2:TRP1; gift from M. Forte, Vollum Institute, Portland, Oregon, USA) (59, 60, S. cerevisiae W301-1B control strain (MATa ade2, leu2, his3, trpl, ura3, can1), and JLI-3 (genotype like W301-1B, aac1:LEU2 aac2:HIS3, aac3:URA; gift from T. Drгон, NIH, Bethesda, Maryland, USA) (61), with NFV, which was followed by treatment with a Vpr-derived peptide (Genemed Synthesis Inc.) as described (62) or H₂O₂ (1 hour, 28°C). This was followed by plating on standard YPD agarose medium (200 yeasts/plate) and quantification of the percentage of surviving clones after 48 hours of culture at 28°C.

**DNA content**

For cell cycle analysis, cells (5 × 10⁶/ml) were spun down and fixed in 70% ice-cold ethanol/PBS, added dropwise while vortexing, kept at −20°C, and centrifuged. Cells were resuspended in 1 ml PBS containing RNase A and 50 μg/ml propidium iodide (Invitrogen Corp.) and analyzed in a cytofluorometer (56). Annexin V and propidium iodide staining. Fifty microliters of annexin binding buffer (BD Pharmingen) was added to 1 × 10⁶ cells in 500 μl of media followed by 2 μl of annexin V–FITC (BD Pharmingen) and 1 μl of propidium iodide (Sigma-Aldrich). The mixture was vortexed and incubated for 30 minutes at 37°C and then subjected to FACS analysis.

**Western blot analysis**

We subjected 40–60 clonal antibody against cytochrome for 15 minutes to fractionate the cytosolic (supernatant) fraction from the mitochondria (52). We subjected 40–60 clonal antibody against cytochrome for 15 minutes to fractionate the cytosolic (supernatant) fraction from the mitochondria (52). We subjected 40–60 clonal antibody against cytochrome for 15 minutes to fractionate the cytosolic (supernatant) fraction from the mitochondria (52). We subjected 40–60 clonal antibody against cytochrome for 15 minutes to fractionate the cytosolic (supernatant) fraction from the mitochondria (52). We subjected 40–60 clonal antibody against cytochrome for 15 minutes to fractionate the cytosolic (supernatant) fraction from the mitochondria (52). We subjected 40–60 clonal antibody against cytochrome for 15 minutes to fractionate the cytosolic (supernatant) fraction from the mitochondria (52).
coated 10-well immunofluorescence slides (Fischer Scientific International) were pretreated with poly-L-lysine (Polysciences Inc.) for 1 hour at RT, washed with water, and allowed to air dry. Fifty microliters of a 0.5 × 10^6 cell suspension was aliquoted to each well and allowed to adhere for 1 hour at 37°C. Following 1 wash with PBS, cells were fixed with 2% paraformaldehyde and washed again with PBS. Cells were then treated with 1:250 of mouse anti-Bax (clone 6A7; BD Biosciences – Pharmingen) or mouse isotype in antibody (Santa Cruz Biotechnology Inc.) in PBS with 1 mg/ml BSA and 100 µg/ml digitonin for 1 hour, followed by 2 washes with PBS. Cells were then incubated for an additional hour at RT in 1:500 of goat anti-mouse Alexa Fluor 633 (Invitrogen Corp.) and 1 mg/ml Hoechst 33342 (Invitrogen Corp.) in PBS with 1 mg/ml BSA and 100 µg/ml digitonin. Cells then underwent a final wash, were coverslipped, and imaged with laser scanning confocal microscopy (LSM510; Zeiss) at an absorption/emission wavelength of 632/647 nm and 340/450 nm for Alexa Fluor 633 and Hoechst 33342, respectively.

Acknowledgments
A.D. Badley is supported by grants from the NIH (R01 Al62261-01-1 and R01 AI40384) and the Burroughs Wellcome Award for Translational Research (ID#1005160). S.A.L. Bennett is supported by grants from Alzheimer Society of Canada, the Canadian Institutes of Health Research (CIHR), and the Alzheimer Society of Saskatchewan. S.A.L. Bennett is a CIHR New Investigator and an Ontario Mental Health Foundation Intermediate Investigator. G. Kroemer is supported by grants from Agence Nationale de Recherche sur le Sida et Sidaction. S.T. Hou is supported by grants from the Heart and Stroke Foundation of Canada. C. Brenner is supported by grants from the Foundation pour la Recherche Medical, the French Ministry of Science, the Centre National pour la Recherche Scientifique, and the Association pour la Recherche sur le Cancer. A. Tarze received a fellowship from the French Ministry of Science. T.C. Moffat received an Alzheimer Society of Canada/CIHR doctoral fellowship. The authors gratefully acknowledge the administrative expertise of A. Carisse and T. Hoff and the technical assistance of A. Desbois and offer special thanks to S. Kilborn and J. Kreye for veterinary assistance and advice.

Received for publication August 5, 2004, and accepted in revised form April 14, 2005.

Address correspondence to: Andrew D. Badley, Division of Infectious Diseases, Mayo Clinic College of Medicine, 200 First Street NW, Rochester, Minnesota 55905, USA. Telephone: (507) 284-3747; Fax: (507) 284-3757; E-mail: badley.andrew@mayo.edu.
